<DOC>
	<DOCNO>NCT01587638</DOCNO>
	<brief_summary>This study use observational , retrospective cohort design compare presence time new-onset diabetes ( NOD ) hypertensive patient initiate therapy carvedilol immediate-release ( IR ) carvedilol controlled-release ( CR ) v follow cardioselective beta blocker ( BBs ) : atenolol , metoprolol succinate , metoprolol tartrate ( referred hereafter 'other BB ' ) . The aim study investigate likelihood develop NOD among hypertensive patient initiate carvedilol therapy v BB therapy real world set derive data contain large United States ( US ) manage care database .</brief_summary>
	<brief_title>Use Beta-blockers Risk New Onset Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Carvedilol</mesh_term>
	<mesh_term>Adrenergic beta-Antagonists</mesh_term>
	<mesh_term>Atenolol</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<mesh_term>Adrenergic beta-1 Receptor Antagonists</mesh_term>
	<criteria>Enrollment plan capture IMS LifeLink Health Plan Claims Database July 1 , 2000 December 31 , 2007 age â‰¥18 year least one pharmacy claim betablocker interest ( carvedilol immediaterelease [ IR ] /controlledrelease [ CR ] , atenolol , metoprolol succinate , metoprolol tartrate ) Index date first chronologically occur prescription betablocker enrollment period Continuously eligible receive healthcare service 6 month prior 3 month index date least 1 diagnosis hypertension ( International Classification Disease , 9th Revision , Clinical Modification ( ICD9CM ) : 401.xx405.xx ) time frame . Diagnosis diabetes mellitus ( ICD9CM : 250.xx ) and/or prescription antidiabetic therapy 6 month prior and/or 3 month index date</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>new-onset diabetes</keyword>
	<keyword>carvedilol</keyword>
	<keyword>claim analysis</keyword>
	<keyword>beta-blocker</keyword>
	<keyword>Diabetes Mellitus</keyword>
</DOC>